Aspen has acquired a range of OTC products from GSK in a multi-territory transaction.
For Australia, the basket of products has sales of around $17 million, with about $750K in New Zealand. Other Asia-Pacific countries coming under the Aspen Australia umbrella represent sales of around $13.5 million.
The products in Australia are Cartia, Zantac, Lipeze, Quellada and Beconase, all well known power brands which will cement the position of Aspen Australia as one of the leading OTC companies in the country.
Aspen, Africa’s largest pharmaceutical manufacturer and the biggest listed pharmaceutical group in the health care sector of the Johannesburg Stock Exchange, through Aspen Pharmacare Australia, one of the leading pharmaceutical companies in Australia, aims to make high-quality branded medicine available to Filipino patients at affordable cost through the launch of its local subsidiary, Aspen Philippines.
In a span of 11 years, Aspen Pharmacare Australia has become one of Australia's leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.
Aspen, South Africa's leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Aspen's high level of flexibility has shown demonstrable business outcomes in addition to the attraction/retention of diverse talent, including consistently meeting sales objectives and extremely high value customer relationships.